Introduction c-Myc is a member of the Myc family of b/HLH/LZ proteins which regulate cell proliferation and apoptosis. Expression of Myc proteins is deregulated in approximately one-third of human cancers through a variety of mechanisms (Cole, 1986; Kelly and Siebenlist, 1986; Spencer and Groudine, 1991) . Overexpression of Myc is especially common in certain advanced cancers, such as hormone-independent adenocarcinomas of the breast and prostate, where it is associated with poor prognosis (Berns et al., 1992; Borg et al., 1992; Hehir et al., 1993; Kreipe et al., 1993; Shiu et al., 1993; Watson et al., 1993; Strohmeyer and Slamon, 1994; Bova and Isaacs, 1996; Cher et al., 1996; Jenkins et al., 1997) . However, since deregulation is sucient for oncogenic activation, the involvement of Myc in late stage cancers may be even broader than suggested by these studies.
c-Myc has a central and necessary role in the proliferation of normal cells. Following mitogenic stimulation of quiescent cells, Myc is rapidly induced and remains elevated, suggesting that it is required for continuous cell growth. Although its exact function remains unclear, Myc appears to be needed at several points during the cell cycle (Evan and Littlewood, 1993) . Induction of Myc is sucient to drive quiescent cells into the cell cycle (Eilers et al., 1989) , while inhibition of Myc can block mitogenic signals and facilitate cell dierentiation (Heikkila et al., 1987; Holt et al., 1988; Sklar et al., 1991; Sawyers et al., 1992; Hanson et al., 1994) . Recent reviews have comprehensively surveyed the numerous investigations aimed at understanding how c-Myc drives cell cycle progression, proliferation, and malignant transformation (Henriksson and LuÈ scher, 1996; Lemaitre et al., 1996; Ryan and Birnie, 1996; Grandori and Eisenman, 1997; Amati et al., 1998; Bouchard et al., 1998; Facchini and Penn, 1998; Dang, 1999 ; and reviews in this issue).
In the early 1990s Cleveland and Evan and their colleagues established de®nitively that c-Myc can also activate apoptosis (Askew et al., 1991; Evan et al., 1992) , a cell suicide program that is intrinsic to metazoan cells (Kerr et al., 1972; Wyllie, 1993) . Toxic eects of elevated c-Myc expression were noted anecdotally by many investigators in the 1980s and reported by several laboratories (e.g. see studies cited in Packham and Cleveland, 1995) . However, before apoptosis became accepted as a bona ®de cellular process, the toxicity of deregulated c-Myc was not conceptualized as a potential function. An early study by Wyllie and colleagues was a harbinger of this paradigm shift (Wyllie et al., 1987) . The capacity of cMyc to drive apoptosis in vitro was ®rst credibly established under growth limiting conditions where its expression was enforced and uncoupled from growth factor controls. Thus, following growth factor withdrawal, cells that contain normal c-Myc downregulate its expression and exit the cell cycle, whereas cells where c-Myc is enforced maintain its expression and undergo apoptosis . A complete survey of initial investigations of the apoptotic properties of cMyc is provided in three initial excellent reviews which helped to frame the questions, models, terminology, and discussion in this area (Harrington et al., 1994b; Packham and Cleveland, 1995) . Among the more important initial questions were whether the death-dealing aspect of c-Myc was due to an intrinsic function or not and how this aspect was regulated and mediated. Here we consider advances made on these issues, beginning by introducing c-Myc, the basic machinery of apoptosis, and the signi®cance of apoptosis to cancer. The ®ndings of biological studies are outlined and a modi®ed version of the dual signal model for c-Myc function is framed. Progress in identifying regulatory and eector mechanisms involved in apoptosis by c-Myc are surveyed and some pressing questions are posed.
c-Myc structure and function
While its exact role in the cell remains a subject of some debate, an extensive body of work argues strongly that c-Myc acts chie¯y in the guise of a transcription factor (Henriksson and LuÈ scher, 1996; Lemaitre et al., 1996; Prendergast, 1997; Facchini and Penn, 1998) . c-Myc is the main member of a nonredundant family of Myc proteins that also includes N-Myc, L-Myc, S-Myc, and B-Myc. myc genes appear to have arisen relatively late in evolution and functional homologs have not been de®nitively identi®ed in organisms more primitive than Drosophila (Gallant et al., 1996; Schreiber-Agus et al., 1997) . Like other Myc proteins, c-Myc is roughly tripartite in organization, with the crucial regions needed for proliferation, apoptosis, and transcriptional activities located in its terminal domains (see Figure 1 ). The C-terminal domain (CTD) includes a basic domain/helix ± loop ± helix/ leucine zipper (b/HLH/Z) motif that mediates oligomerization through the HLH/Z region and speci®c DNA recognition of CACGTG E box motifs present in all target genes through the basic domain (Blackwell et al., 1990; Halazonetis and Kandil, 1991; Kerkho et al., 1991; . Overexpression of heterologous dimers of the c-Myc basic region dominantly interfered with malignant transformation by c-Myc, oering initial genetic proof that CACGTG is a physiological Myc recognition site . However, Myc proteins do not homo-oligomerize in cells. Physiological DNA binding and biological activity depends upon hetero-oligomerization with Max, a small, nonredundant, and ubiquitously expressed protein comprised essentially of a b/HLH/Z domain (Blackwood and Eisenman, 1991; Wenzel et al., 1991; Blackwood et al., 1992; Kato et al., 1992; Reddy et al., 1992; Ferre-D'Amare et al., 1993; Ma et al., 1993) . Phosphorylation and alternate splicing proximal to the basic region inhibit the ability of Max homodimers to associate with DNA in cells (Berberich and Cole, 1992; Prochownik and Van Antwerp, 1993; Zhang et al., 1997) . Max association and DNA binding are required for transcriptional activation of target genes by c-Myc as well as its ability to drive proliferation, malignant cell transformation, and apoptosis (Amati et al., 1992; Kretzner et al., 1992a,b; MaÈ kelaÈ et al., 1992; Mukherjee et al., 1992; Prendergast et al., 1992; Amati et al., 1993a,b; Gu et al., 1993) . Access to CACGTG binding sites in target genes may be regulated by CpG methylation of the central dinucleotide . The CTD interacts with proteins in addition to Max including YY-1, AP-2, BRCA-1, TFII-I, and Miz-1, which all appear to in¯uence DNA binding by c-Myc/Max complexes in some fashion (see LuÈ scher and Larsson, this issue). AP-2 has been implicated in suppressing apoptosis by c-Myc (Moser et al., 1997) but possible roles for the other factors in cell death has not been examined. In summary, the CTD is devoted to speci®c DNA recognition by c-Myc and regulation of its access to speci®c DNA binding sites.
The N-terminal domain (NTD) includes the transcriptional activation domain (TAD) of Myc and probably other functions. Two *20 aa segments in the NTD termed Myc boxes 1 and 2 (MB1 and MB2) are conserved in all Myc family proteins and are crucial for all biological activities. The ®rst glimpse of the function of this region was provided by the observation that the NTD activated transcription when fused to a heterologous DNA binding domain (Kato et al., 1990) . This initial ®nding was later validated by demonstrations that the c-Myc/Max complex could activate transcription from arti®cial promoters as well as from candidate target genes (Amati et al., 1992; Kretzner et al., 1992a; BelloFernandez et al., 1993; Benvenisty et al., 1993; Crouch et al., 1993; Jansen-Durr et al., 1993; Reisman et al., 1993; Wagner et al., 1993a; Gaubatz et al., 1994) . The mechanism through which the NTD activates transcription in unclear. A good candidate, however, has emerged in the ATM-related protein TRRAP, an NTD-binding protein that is part of the SAGA complex which includes histone deacetylases implicated in activation events (Grant et al., 1998; McMahon et al., 1998; Saleh et al., 1998) . The activation activity of the NTD may also be influenced by interactions with the retinoblastoma (Rb)-related protein p107 (Beijersbergen et al., 1994; Gu et al., 1994; Hoang et al., 1995) , whose binding to c-Myc may be modulated by cyclin D/CDK4 phosphorylation (Hass et al., 1997) , or with the adaptor protein and tumor suppressor Bin1 (Sakamuro et al., 1996; Elliott et al., 1999) . The NTD is also reported to interact with a-tubulin (Alexandrova et al., 1995) , PAM, a large protein which includes RCC1-like repeats suggesting a role in chromatin regulation , MM-1, a nucleocytoplasmic adaptor protein that inhibits transactivation by c-Myc, and AMY-1, a small protein reported to potentiate the transactivation activity of cMyc (Taira et al., 1998) . In addition to harboring a transactivation domain, the NTD also mediates transcriptional repression (Kaddurah-Daouk et al., 1987; Suen and Hung, 1991; Yang et al., 1991 Yang et al., , 1993 Jansen-Durr et al., 1993; Roy et al., 1993; Li et al., 1994; Philipp et al., 1994; Lee et al., 1996; Tikhonenko et al., 1997) . Repression of growth arrest genes may be one way in which Myc promotes growth and perhaps apoptosis . Myc box 2 appears to be crucial for repression and transformation (Li et al., 1994; Brough et al., 1995; Lee et al., 1996; Xiao et al., 1998) . Activation is thought to be important for all biological activities, but two recent studies using Rat1 ®broblasts nullizygous for c-myc, which are viable and replicatively competent but which proliferate slowly (Mateyak et al., 1997) , have challenged the role of the transactivation properties of c-Myc in cell proliferation (Bush et al., 1998; Xiao et al., 1998) . Roles for a subset of c-Myc target genes implicated in apoptosis are discussed below. For a full listing and consideration of the 430 reported target genes and their potential roles in mediating the various biological eects of c-Myc the reader is directed to a recent comprehensive review on this topic (Dang, 1999) .
Apoptosis: the basic`executioner' machinery and key pathways to it in cancer Apoptosis (meaning`a dropping o') is an intrinsic cell suicide program that is universal in metazoan organisms. Strictly speaking, apoptosis is de®ned by morphological features. It is characterized by cell shrinkage, violent blebbing of the plasma membrane and chromatin condensation (Wyllie, 1993) . Unlike a necrotic cell, the apoptotic cell does not leak internal contents and it does not induce an in¯ammatory response. The pieces of the cell which remain when the program is complete are termed apoptotic bodies. Many features of apoptosis are not so readily detected in vivo as might be expected because soon after the death program is engaged cells are quickly recognized by macrophages and engulfed. Neighboring cells may also perform this act. Engulfment is triggered by the appearance of phosphatidylserine on the outer lea¯et of the plasma membrane of the dying cell, a process which is catalyzed by an activated`¯ipase'. Apoptosis is a Figure 1 Myc structure and major binding proteins. The CTD harbors the b/HLH/Z motif for oligomerization and DNA binding and the NTD harbors evolutionarily conserved`Myc boxes' 1 and 2 (MB1 and MB2). Both terminal domains are required to regulate transcription of target genes, drive cell cycle transit, cause malignant transformation, and activate apoptosis. Max is a physiological partner for c-Myc that binds to the CTD and mediates DNA binding as a heterodimer with c-Myc. Max is necessary for both transformation and apoptosis. Miz-1, TFII-I, and other proteins also associate with the CTD. MB1 is the target of phosphorylation by Cdk and Gsk-3. The central domain between the NTD and CTD is largely dispensable. The adaptor protein Bin1 and the ATM-related protein TRRAP are NTD-binding proteins implicated in apoptosis and transformation, respectively. TRRAP may mediate transcriptional eects since it is part of the SAGA complex, which contains histone acetylases that globally control chromatin state and transcription. p107 may co-ordinate c-Myc activity with the cell cycle. PAM has RCC1-like repeats suggesting a role in chromatin modeling or cell cycle default which is engaged unless cells receive sucient survival signals to negate it (Ra, 1992) .
Key advances in the molecular understanding of apoptosis were realized by genetic analysis of the development of the soil nematode Caenorhabditis elegans (Ellis et al., 1991) . The lineage and fate of all the somatic cells in this genetically malleable organism are known and 131 cells die by apoptosis during development. By analysing mutant nematodes that had abnormal numbers of cells Horvitz and colleagues were able to clone genes that controlled cell death (ced, cell death abnormal). Three genes cloned in this way, ced-3, ced-4, and ced-9, proved to encode the central regulatory machinery of apoptosis, sometimes referred to as the`executioner' machinery, which is conserved in evolution between C. elegans and mammals (Yuan, 1996) . Genetic analysis demonstrated that ced-9 suppresses activation of ced-3 by ced-4 through direct biochemical interactions (Metzstein et al., 1998) . The blueprint provided by C. elegans has helped guide mammalian cell studies. Figure 2 presents the components of the fundamental executioner machinery and selected key pathways which regulate it.
ced-9 proved to be homologous to the mammalian protein Bcl-2, an antiapoptotic protein cloned from a follicular B cell tumor which locates mainly to the outer membrane of the mitochondria (Adams and Cory, 1998) . In mammalian cells, the Bcl-2 family includes antiapoptotic members such as Bcl-X L and proapoptotic members such as Bax, Bak, Bid, and Bad (Adams and Cory, 1998) . Current understanding of this important class of cell survival regulators suggest that they control the status of the permeability transition (PT) in mitochondria and the eux of ions or proteins, most notably the electron transport protein cytochrome c (Chao and Korsmeyer, 1998; Green and Reed, 1998) . Possibly through their ability to form multimeric pore-like complexes, antiapoptotic members including Bcl-X L and Bcl-2 are believed to inhibit eux whereas a subset of proapoptotic members including Bax are believed to oppose this process and promote eux (Adams and Cory, 1998) . Most proapoptotic members, such as Bad and Bid, lack features suggesting pore-forming roles and instead have a single ligand binding domain (BH3 domain) which may act by displacing proapoptotic proteins from antiapoptotic partners and promoting the pore-forming action of the former (Kelekar and Thompson, 1998) . Bcl-2 family proteins interact with each other and the ratio of active proapoptotic to antiapoptotic proteins is a critical determinant of cell survival. There appear to be preferences for association, for example, Bcl-2/Bax and Bcl-X L /Bad. The function of some Bcl-2 family proteins is regulated by posttranslational phosphorylation (Chao and Korsmeyer, 1998) . For example, microtubule disrupters cause Bcl-2 to become phosphorylated in tumor cells by Raf (Blagosklonny et al., 1997) , whereas Bad is downregulated by activation of the phosphatidylinositol-3'-kinase (PI3'K)-Akt kinase cell survival pathway (Datta et al., 1997) .
ced-3 was found to be similar to IL-1b-converting enzyme (ICE), a proenzyme processing cysteine protease that proved to have proapoptotic properties (Thornberry and Lazebnik, 1998) . The ICE-related proteases, of which there are currently 14, are characterized by cysteine speci®city and have been termed caspases (Thornberry and Lazebnik, 1998) . Caspases are synthesized as inactive precursors and activated either by autocleavage, when concentrated at certain loci in cells, or by cleavage by another caspase, which in either case generates an active heterodimer composed of *10 kD and *20 kD subunits. Caspases have long or short N-terminal prodomains. Those with long prodomains (regulatory caspases) cleave and activate those with short prodomains (eector caspases). Caspases of special relevance to cancer are caspase-3, which is responsible for chromatin collapse and DNA degradation (Woo et al., 1998) , caspase-8, which is the ®rst caspase in the CD95/Fas pathway (Ashkenazi and , and caspase-9, which is activated by Bcl-2 familydependent events at mitochondria and is responsible for cleavage and activation of caspase-3 (Li et al., 1997; Zou et al., 1997) . Notably, oncogenes including c-Myc potentiate the activation of caspase-9 in cells through as yet unde®ned mechanisms (Fearnhead et al., 1997 (Fearnhead et al., , 1998 . More than 40 caspase substrates have been de®ned whose cleavage is believed to be important to cell demise. Among the most crucial substrates is the apoptotic DNA endonuclease DFF/ CAD, which is expressed as an inactive precursor complex with the inhibitor ICAD and which is cleaved and activated by caspase-3 Enari et al., 1998) . A wide variety of caspase inhibitors have been characterized, increasing the complexity of caspase regulation in mammalian cells (Thornberry and Lazebnik, 1998) .
In an elegant set of biochemical experiments Wang and colleagues identi®ed the mammalian homolog of ced-4, termed Apaf-1, through its ability to activate caspase-3 . Necessary cofactors that puri®ed in a complex with Apaf-1 were cytochrome c, a key member of the electron transport chain located in mitochondria, dATP, and caspase-9 (Li et al., 1997) . Apaf-1 is cytosolic and cytochrome c is normally found in mitochondria, implying that mitochondria-dependent cytochrome c release is necessary for Apaf-1 to promote apoptosis. The link to mitochondria provides the connection to Bcl-2 family proteins which are believed to act there as ion and/or protein channels or possibly as regulators of such channels (Green, 1998; Green and Reed, 1998; Reed et al., 1998) . As mentioned above, cytochrome c release can be elicited by proapoptotic members of the Bcl-2 family and also by calcium (Eskes et al., 1998) . In addition, biochemical analyses have implicated adenovirus E1A, c-Myc, and p53 in promoting cytochrome c release and caspase activation through some undefined mechanism(s) (Fearnhead et al., 1997 (Fearnhead et al., , 1998 . The relevant connections and whether they involve calcium or Bcl-2 family proteins should emerge shortly. However, in whatever way it is released, cytochrome c association with Apaf-1 in the presence of bound dATP leads to a recruitment and aggregation of caspase-9 that triggers its autocleavage and activation. Only mitochondrially assembled (i.e. hemebound) cytochrome c will stimulate Apaf-1, reinforcing the role of mitochondria in regulating activation of caspase-9. The biochemical complex carrying out this process (minimally comprised of Apaf-1, cytochrome c, dATP, and caspase-9) has been termed an`apoptosome' since it is sucient to elicit apoptosis in cells. Mammalian Apaf-1 includes in its C-terminal domain a set of WD40 repeats which may regulate the ability to activate caspase-9 . Consistent with the C. elegans blueprint, Bcl-X L can form a ternary complex with Apaf-1 and caspase-9 (Pan et al., 1998) . Additional Bcl-2 family proteins have been identi®ed that interact directly with Apaf-1, termed Diva and Boo. Diva is a proapoptotic protein that acts via a BH3-independent mechanism (Inohara et al., 1998) . Boo is an antiapoptotic protein whose interaction with Apaf-1 is displaced by the BH3-dependent proapoptotic proteins Bak and Bik. A central role of Apaf-1 in mammalian cell apoptosis and mouse development has been demonstrated and, as expected, cells lacking Apaf-1 exhibit defects in the ability to activate apoptosis by many stimuli (Cecconi et al., 1998; Yoshida et al., 1998) . However, some Apaf-1-independent apoptosis induced by certain stimuli (e.g. staurosporine) raised the possibility that additional Apaf-1-like proteins may exist.
Three pathways which lead to the basic executioner machinery deserve special mention with regard to cMyc and cancer (see below). The ®rst is the p53-Bax pathway. p53 is a checkpoint regulator and tumor suppressor that is activated by DNA damage and certain other stresses (Levine, 1993) . Under catastrophic circumstances p53 will trigger apoptosis in part by stimulating expression of Bax, which is a target of transcriptional activation by p53 (Miyashita et al., 1994; Selvakumaran et al., 1994a; Miyashita and Reed, 1995) . Elevation of Bax by p53 is not a sucient cause for the latter to drive apoptosis; this also requires an unde®ned signal from the speci®c apoptosis eector domain of p53 (Sakamuro et al., 1997) . Nevertheless, Bax elevation tilts mitochondria toward cytochrome c release and activation of caspase-9, which stimulates caspase-3 activity and cell demise. A second pathway linked to the executioner machinery in cancer cells is the PI3'K-AKT survival pathway. This pathway can be activated by a variety of stimuli, including integrin-dependent cell adhesion, ligation of the receptors for insulin-like growth factor-1 (IGF1) or IL-3, and activated Ras (Datta et al., 1997; del Peso et al., 1997; Franke et al., 1997; Frisch and Ruoslahti, 1997; Khwaja et al., 1997; King et al., 1997; Liu et al., 1998) . Two substrates in the executioner machinery for the AKT kinase which have been identi®ed are Bad and caspase-9 (Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998) . A recent report suggests that a BAD may also be targeted for phosphorylation via a PI3'K-independent pathway involving MEK (Scheid and Duronio, 1998) . AKT phosphorylation of Bad leads to loss of its proapoptotic activity, probably by aecting its ability to associate with Bcl-X L . Similarly, AKT phosphorylation of caspase-9 reduces its proteolytic activity (Cardone et al., 1998), illustrating two levels at which AKT targets the executioner machinery for inhibition. A third set of related executioner pathways of interest to c-Myc are those activated by cell surface ligation of the death receptors CD95/Fas, which depending on cell type either bypasses or involves mitochondria (Type I or Type II; Scadi et al., 1998; Green, 1998) , or certain members of the TNF-R family, which depending on receptor type may stimulate both death and NF-KB-dependent survival signals (Ashkenazi and Dixit, 1998) . Death in each case is mediated by direct activation of caspase-8, which autocleaves following its recruitment and aggregation by the receptor-binding death eector domain (DED) adaptor proteins FADD to CD95/Fas or FADD+TRADD to TNF-R. Depending on cell and receptor type, robust activation of caspase-8 occurs, leading directly to caspase-3 activation and cellular demise, or weaker activation of caspase-8 occurs, followed by cleavage of the proapoptotic Bcl-2 protein Bid, which stimulates cytochrome c release and activation of caspase-3 via caspase-9 cleavage Luo et al., 1998) . CD95/Fas and TNF-R pathways may be mechanistically crucial in many cell death settings, including cancer.
Apoptosis: its signi®cance in cancer
Apoptosis has many roles in development and homeostasis and its dysregulation is a hallmark of many diseases (Peter et al., 1997) . One of its crucial roles is to limit inappropriate cell proliferation that can lead to cancer (Evan and Littlewood, 1998) . Apoptosis can stanch such proliferation but apoptotic mechanisms are progressively eliminated during neoplastic progression (Williams, 1991) . Substantial clinical evidence argues that this progressive elimination is a crucial step in malignant conversion, for example, in the progression of prostate carcinoma to hormone independence (Kyprianou et al., 1990; McDonnell et al., 1992; BraÈ ndstroÈ m et al., 1994; Rao et al., 1995) . This is not due to loss or inactivation of the basic machinery of apoptosis, which remains intact even in advanced malignancies (Martin and Green, 1995) . For example, in vitro studies of estrogen-independent breast tumor cells have indicated that they retain an intrinsic capacity for apoptosis, even though they are resistant to hormone deprival (Kyprianou et al., 1991; Armstrong et al., 1992) . Neoplastic cells are resistant to apoptosis apparently because they lack or suppress the regulatory mechanisms required to activate the basic executioner machinery. Mutation of p53 or elevation of antiapoptotic members of the Bcl-2 family are paradigms in cancer. As outlined above, activation of AKT by various means in cancer cells is also likely to be important (Franke et al., 1997; Frisch and Ruoslahti, 1997; Ruggeri et al., 1998; Wu et al., 1998) . However, the executioner machinery remains intact in cells transformed by c-Myc, which may oer an Achilles' heel to exploit. Consistent with this notion, latent but as yet unde®ned activators of caspases are clearly present in cells c-Myc-transformed cells but not in normal cells (Fearnhead et al., 1997; Ding et al., 1998) . Thus, the interface between c-Myc and the executioner machinery oers a logical realm to identify novel therapeutic strategies.
c-Myc induces apoptosis
c-Myc is sucient and necessary for apoptosis under certain conditions. The initial observations establishing this were made in IL-3-dependent murine myeloid 32D cells, primary and established rat ®broblasts, and T cell hybridomas. Askew et al. (1991) showed that constitutive expression of c-Myc markedly accelerated apoptosis of 32D cells denied IL3. Death was not restricted to a particular phase of the cell cycle but occurred in all phases, and c-Myc continued to drive S phase entry of cells which did not immediately commit suicide. demonstrated conclusively that c-Myc was sucient to elicit apoptosis in primary rodent embryo ®broblasts (REFs) or established Rat1 ®broblasts deprived of growth factors. This study was based on resolution of the fulcrum observation that c-Myc was not able to drive outgrowth of a cell population cultured at suboptimal serum concentrations, even though in the same population c-Myc was clearly stimulating cell cycle transit. The reason behind this apparent discrepancy was that cell death and cell division was occurring simultaneously in dierent cells in the population. The cell death that was occurring had all the features of apoptosis. As in 32D cells apoptosis, occurred in all phases of the cell cycle, in a stochastic fashion such that some cells in the population died while other cells continued to proliferate through the in¯uence of c-Myc. The stochastic feature, which was the basis for the initial apparent conundrum, remains an enduring mystery in apoptosis not only by c-Myc but generally. Notably, additional growth limiting treatments such as amino acid deprivation were similarly capable of eliciting apoptosis by c-Myc, raising the possibility that a con¯ict of growth and arrest signals in cells might be the cause of apoptosis rather than a direct function of c-Myc . A rudimentary genetic analysis performed using a canonical set of cMyc deletion mutants (Stone et al., 1987) indicated overlap in the terminal regions of c-Myc required for apoptosis or transformation, illustrating crucial requirements for the Myc Box-containing NTD and the b/ HLH/LZ-containing CTD . Cell death by c-Myc in the Rat1 system was subsequently shown to be associated with the activation of certain Jun kinases (Jnks) and caspase-3 (Kagaya et al., 1997; Yu et al., 1997; Kangas et al., 1998) , which is crucial to produce the associated chromatin collapse and nucleosomal DNA degradation. c-Myc is also responsible for cell death in Burkitt's lymphoma cells and EBVimmortalized B cells deprived of autocrine factors (Milner et al., 1993; Cherney et al., 1994) . Lastly, epithelial cells have also been shown to be susceptible to apoptosis by c-Myc (Sakamuro et al., 1995) . Malignant transformation of epithelia in lung, colon, breast, prostate, cervix and liver presents a well-known and grim clinical challenge. However, epithelial cells are not only susceptible to c-Myc but can be killed via multiple mechanisms, some of which appear to be unavailable in ®broblasts or hematopoietic cells (Sakamuro et al., 1995; Lanoix et al., 1996; Trudel et al., 1997) . Together these studies showed that c-Myc is a sucient cause of apoptosis.
A necessary role for c-Myc in apoptosis was reported by Shi et al. (1992) who used antisense oligonucleotides to reduce c-Myc expression in murine T hybridomas and show that c-Myc was required for apoptosis induced by T cell receptor activation. Later studies established that c-Myc was a critical determinant of apoptosis induced by TNF-a (Janicke et al., 1994; Klefstrom et al., 1994; Dong et al., 1997) and of the magnitude of the response to ligation of the CD95/ Fas death receptor (Hueber et al., 1997) . However, it now appears that c-Myc is required for ecient response to a variety of apoptotic stimuli, including transcription and translation inhibitors, hypoxia, glucose deprival, heat shock, chemotoxins, DNA damage, and cancer chemotherapeutics Harrington et al., 1994a; Wagner et al., 1994; Yao et al., 1995; Alarcon et al., 1996; Graeber et al., 1996; Jiang et al., 1996; Kang et al., 1996; Li et al., 1996; Dong et al., 1997; Koumenis and Giaccia, 1997; Zhan et al., 1997; Nesbit et al., 1998; Rupnow et al., 1998; Shim et al., 1998) . Evan and Littlewood have proposed the appealing idea that c-Myc does not act as a death eector in all these instances but instead acts to sensitize cells to a variety of apoptotic triggers (Evan and Littlewood, 1998) . In any case, its role in death by so many stimuli supports the hypothesis that c-Myc has intrinsic function related to cell death.
Retroviral myc proteins (v-myc proteins) and other Myc family members also have the capacity to induce apoptosis. v-myc proteins mimic c-Myc despite the fact that they include a variety of sequence alterations which might have been thought to ablate apoptotic properties (Troppmair et al., 1992; Wang et al., 1993a,b; Dolnikov et al., 1996) . Indeed, a comparison of c-Myc and v-Myc in avian cells indicated that the latter induced apoptosis more potently (Petropoulos et al., 1996) . The tight association between these properties in retroviral oncogenic myc genes, where strong selective pressures would be expected to rid death-dealing aspects, reinforces the notion that they are inseparable at the level of the protein and therefore coordinately controlled together. Investigations of the capacity of N-Myc and L-Myc to drive cell death have revealed similarities to c-Myc (Zornig et al., 1995; Ueda and Ganem, 1996; Chernova et al., 1998; Lutz et al., 1998; Nesbit et al., 1998) . The antiproliferative S-Myc protein also induces apoptosis but without the need for a growth factor deprivation trigger (Asai et al., 1994) . A comparison of the eects of N-Myc, L-Myc, and c-Myc in 32D myeloid cells indicates that they dierentially sensitize cells to some stimuli (Nesbit et al., 1998) . The literature provides counter examples where under growth limiting conditions c-Myc can promote survival of B lymphocytes (Wu et al., 1996a; Sonenshein, 1997; Wang et al., 1999) or dierentiation of normal human keratinocytes (Gandarillas and Watt, 1997) , illustrating the complex cell fate regulating aspects of c-Myc. However, the clear trend in the great majority of cell types examined is for Myc proteins to promote both mitogenesis and cell death under growth limiting conditions.
The cooperation in tumorigenesis between c-Myc and Bcl-2 (Strasser et al., 1990) , a gene discovered at a chromosomal breakpoint in a follicular B cell tumor (Tsujimoto et al., 1984) and then subsequently identi®ed as an apoptosis suppressor that can cooperate with c-Myc in cell immortalization (Vaux et al., 1988) , made it likely that Bcl-2 would block apoptosis by c-Myc. Several studies have explicitly con®rmed this expectation in mesenchymal cells Fanidi et al., 1992; Wagner et al., 1993b; Wang et al., 1993b) . This work helped establish the principle that manifestation of the full oncogenic properties of c-Myc may require loss or suppression of apoptosis Facchini et al., 1994) . The ability of other oncogenes to collaborate with myc in lymphomagenesis, including ras, raf, pim-1 and v-abl, suggests that these oncogenes can also provide as part of their action an antiapoptotic signal which negates the death-dealing aspect of c-Myc (Adams and Cory, 1992) . How these genes, and in particular Bcl-2, impinge mechanistically on c-Myc remains unclear. For example, Bcl-2 does not block apoptosis by c-Myc in certain epithelial tissues (Trudel et al., 1997) . Moreover, caspase inhibitors do not block cell death by c-Myc (although they block apoptotic features associated with it) (McCarthy et al., 1997), even though Bcl-2 family proteins are thought to block death by inhibiting activation of Apaf-1 and thereby caspases (Adams and Cory, 1998; Green and Reed, 1998; Reed et al., 1998) . Finally, it is important to note that Bcl-2 proteins act by aecting the kinetics of death in cells expressing c-Myc, which are certainly important in cancer cells, rather than by inhibiting signals for death commitment (McCarthy et al., 1997) , about which little seems to be known. Thus it seems that cMyc and other proapoptotic oncogenes coordinately induce signals for death commitment and caspase activation. Emerging caspase-independent aspects of apoptosis (e.g. Quignon et al., 1998; Wang et al., 1998b) may give insights into the manner in which a death commitment signal is generated and into the exact relationship between c-Myc and mitochondrial events that are regulated by the Bcl-2 family. p53: obligate eector or simply death sensitizer?
The role of p53 in apoptosis by many stimuli is wellestablished but its exact role in apoptosis by c-Myc is uncertain. Several in vitro studies have argued that p53 is crucial. Mouse embryo ®broblasts from p53 null animals are largely refractory to apoptosis by c-Myc (Hermeking and Eick, 1994; Wagner et al., 1994) , and similar results have been obtained in other mesenchymal cell types (Wang et al., 1993a; Hermeking et al., 1994; Bennett et al., 1995; Yu et al., 1997) . Some investigators also observed elevation of p53 levels by ectopic c-Myc expression (Hermeking and Eick, 1994; Yu et al., 1997) , in support of the candidacy of p53 as a Myc target gene (Reisman et al., 1993) , although this eect has not been observed widely. However, results from other studies which included in vivo assays and epithelial cell models argued against an obligate role for p53 (Hsu et al., 1995; Sakamuro et al., 1995; Lenahan and Ozer, 1996; Trudel et al., 1997) . For example, even though c-Myc induces lymphomas more rapidly in p53 null mice (Elson et al., 1995) , a careful examination showed this was due to enhanced proliferation and not to reduced apoptosis (Hsu et al., 1995) . In addition, expression of SV40 T antigen, which inactivates both p53 and Rb, or adenovirus E1B 55 kD protein, which inactivates p53, did not aect the ability of c-Myc to induce apoptosis in established Rat1 cells (Harrington et al., 1994b; Lenahan and Ozer, 1996) . Finally, overexpressed c-Myc induces apoptosis in M1 myeloid cells, which lack a p53 gene (Selvakumaran et al., 1994b; Lotem and Sachs, 1995) . Tissue speci®c dierences may dictate the mechanisms used by c-Myc. In baby rat kidney (BRK) cells, c-Myc induces apoptosis by both p53-dependent or p53-independent mechanisms (Sakamuro et al., 1995) . The lack of a p53 requirement for apoptosis was con®rmed in kidney epithelia in myc transgenic mice (Trudel et al., 1997) . It is interesting to note in this context that p53 inactivation does not cooperate with c-Myc to promote malignant transformation of mammary epithelial tissues (Elson et al., 1995) . Thus, p53-independent mechanisms may be predominant in epithelial cells. A complex relationship between c-Myc and p53 is suggested by the following observations. Interestingly, mutant p53 suppresses apoptosis by cMyc in M1 myeloid cells, even though they are nullizygous for p53 (Lotem and Sachs, 1995) . This eect is presumably dictated by the ability of mutant p53 to interact directly or indirectly with a factor required by c-Myc to induce death. The results of a study examining the eects of c-Myc on TNF killing con®rm some type of crosstalk between c-Myc and p53. In this study, it was noted that p53 null cells were refractory to c-Myc sensitization to TNF, but this phenotype could not be replicated by overexpression of a C-terminal dominant inhibitory fragment of p53 (Klefstrom et al., 1997) . Thus, the presence of unoligomerized wild-type p53, which would be expected to be transcriptionally inactive, was sufficient to allow c-Myc sensitization. Thus, some transactivation-independent aspect of p53 is crucial. One interpretation of these data is that c-Myc and p53 interact with some common apoptosis eector signaling system, perhaps involving the apoptosis eector domain in p53, as we have speculated previously (Sakamuro et al., 1997) . This idea is supported by a recent study of the p53-interacting modulator p33 ING1 in cells where apoptosis is induced by c-Myc, which suggests that p53 and c-Myc may have parallel actions (Helbing et al., 1997) . In any case, it is conceivable that p53 or c-Myc may sensitize cells to each other or to other proapoptotic triggers, an idea related to that proposed by Evan and Littlewood (1998) to explain the proapoptotic actions of oncogenes. Further investigations are needed to understand what is apparently a complex relationship between c-Myc and p53. p19 ARF , the alternate reading frame product of the Ink4 tumor suppressor gene, has been implicated recently as a link between p53 and c-Myc in apoptosis . Ink4 is among the most frequently mutated tumor suppressor genes in human cancer. It encodes p16
INK4
, a cell cycle kinase inhibitor (CKI) that is crucial for proper regulation of the retinoblastoma (Rb) protein, as well as p19 ARF , a protein that interacts with and regulates the p53-Mdm2 complex (Sherr, 1998) . Thus, the Ink4 gene encodes two structurally unrelated tumor suppressors that interact with the two most important growth regulatory circuits in the cell. It was noted that mouse embryo ®broblasts (MEFs) lacking the p19 ARF gene could be transformed by oncogenic Ras alone, suggesting that c-Myc might regulate p19 ARF . In support of this hypothesis, introduction of c-Myc into wild-type MEFs elevated p19 ARF and p53 and triggered crisis and apoptosis, whereas cMyc had little eect on p53 or apoptosis in p19 ARF7/7 MEFs. Wild-type MEFs transfected with c-Myc that emerged as immortal clones invariably sustained mutation of p53 or deletion of p19 ARF . p19 ARF7/7 and p53 7/7 MEFs were readily immortalized by cMyc but exhibited an attenuated death response to serum deprival . Following a wave of apoptosis which eliminated a large fraction of the cell population, the remaining cells could be passaged inde®nitely in the absence of serum. The initial wave of apoptosis apparently re¯ects a p19 ARF /p53-independent mechanism of the type discussed above. Nevertheless, loss of p53 or p19 ARF tolerized a signi®cant portion of the cell population to the cytotoxic eects of c-Myc. p19
ARF is expressed from a speci®c promoter in the Ink4 gene that includes Myc-like E box motifs (C Sherr, personal communication), making it a logical target gene candidate. Whether p19 ARF plays a similar role for c-Myc in other cell types and organisms is not yet clear. Rat1 ®broblasts appear to have both intact wild-type p53 and p19
ARF genes (J Sedivy, personal communication), which may explain why they are so sensitive to apoptosis by c-Myc, but it is notable that neither gene was mutated during establishment of these cells. In MEFs, p19 ARF responds similarly to ectopic expression of E1A and provides a link to Mdm2 through E1A mediates p53 stabilization (de Stanchina et al., 1998) . How E1A induces p19 ARF is unclear. Zindy et al. (1998) proposed that p19
ARF regulates a p53-dependent checkpoint that safeguards cells against hyperproliferative and oncogenic signals. That p19 ARF is dispensable for cell proliferation and possibly a c-Myc target gene speci®cally involved in apoptosis impacts the dual signal model for c-Myc function considered below.
Myc target genes and apoptosis
A growing number of genes have been identi®ed as targets for regulation by c-Myc and it seems likely that more will follow (Dang, 1999) . Two recent studies raise concerns about physiological validation (Bush et al., 1998; Xiao et al., 1998) . Using c-myc null cells (Mateyak et al., 1997) to assess the serum response of the best-studied target genes, it was found that only the cad and gadd45 genes were misregulated in the absence of c-Myc (Bush et al., 1998) . cad is a housekeeping gene that participates in pyrimidine biosynthesis which is activated by cMyc (Miltenberger et al., 1995; Boyd et al., 1998) , but it has not been assigned any role in apoptosis to date. gadd45 (growth arrest and DNA damageinducible gene 45) is functionally unde®ned and repressed by c-Myc (Marhin et al., 1997) ; it also has not been assigned any role in cell death. It is notable that of the 430 candidate genes identi®ed to date, few seem as robustly regulated as the targets of better understood transcription factors. Although biochemical crosslinking methodologies suggest that there may be many c-Myc binding sites in the genome (Boyd et al., 1998) , recent cell biological experiments suggest the number of physiological sites may be relatively small (Rudolph et al., 1998) . In these experiments, primary REFs were transfected with multimerized wild-type physiological DNA binding sites or point-mutated versions of the same and cell clones were selected and monitored for the number of passages to arrive at replicative crisis. Interestingly, clones containing as few as *50 copies of the wild-type E box sequences underwent crisis signi®cantly more quickly than controls (Rudolph et al., 1998) . If, as expected, these sequences compete with physiological sites for binding to c-Myc, then these results imply that the number of loci needed for c-Myc to drive proliferation are comparatively few. If so, many genes which score as c-Myc targets may be fortuitously rather and physiologically regulated.
That caveat stated, there is evidence that some of the existing targets indeed mediate some of the biological eects of c-Myc, and several linked to apoptosis are surveyed here. Ornithine decarboxylase (ODC) is perhaps the best studied target of c-Myc (BelloFernandez et al., 1993; Wagner et al., 1993a; Tobias et al., 1995; Wu et al., 1996b; Packham and Cleveland, 1997; Ben-Yosef et al., 1998) . Signi®cantly, ODC has been shown to be necessary and sucient for apoptosis by c-Myc in 32D myeloid cells (Packham and Cleveland, 1994 ). ODC does not drive cell death nearly as eciently as c-Myc but in support of its role it has been reported to be an important participant with c-Myc in chemotoxin-induced cell death (Zhan et al., 1997) . ODC is a housekeeping enzyme involved in polyamine synthesis and is necessary for cell proliferation. How it impacts apoptosis is unclear, although one possibility is that excess polyamine catabolism generates reactive oxygen species (ROS) which promote mitochondriadependent apoptosis (Packham and Cleveland, 1995) . ODC has overlapping roles in death and proliferation (Auvinen et al., 1992; Moshier et al., 1993; Packham and Cleveland, 1994; Shantz and Pegg, 1994) .
Several genes that promote cell cycle transit have been suggested as c-Myc targets (Dang, 1999) and two of these, cyclin A and Cdc25A, have been suggested to participate in apoptosis by c-Myc (Hoang et al., 1994; Galaktionov et al., 1996) . Integrins regulate cyclin A, which associates with CDK2 and promotes S phase progression. Enforced expression of cyclin A in Rat1 cells is sucient to confer anchorage-independent growth capacity and susceptibility to apoptosis by serum deprival (Hoang et al., 1994) . Cdc25A is a phosphatase responsible for activating cdc2. Cdc25A has been reported to be both necessary and sucient for apoptosis by c-Myc (Galaktionov et al., 1996) . Although this observation has not been extended, it is consistent with suggestions of a role in apoptosis in particular settings for aberrant activation of cdc2 (also a putative target gene [Born et al., 1994] ) (Shi et al., 1994; Chen et al., 1995) . Three other cell cycle regulators that are not genetic targets of c-Myc, Cdk2, Cdk3, and cyclin D3, have also been reported to enhance apoptosis by c-Myc (Janicke et al., 1996; Braun et al., 1998) . Early ideas that apoptosis might have features of inappropriate mitosis stimulated investigations of cell cycle-related genes in apoptosis. However, these ideas have been challenged recently because positive associations with death have not been widely generalized. One study that employed a variety of cell cycle inhibitors concluded that Cdks are dispensable for apoptosis (Rudolph et al., 1996) . In addition, a more recent study noted that Cdk2 and Cdc25A message levels reacted similarly in Rat1 cells, whether they underwent apoptosis in the presence of deregulated c-Myc or simply exit to G0 in its absence (Helbing et al., 1998) . The status of Cdks in apoptosis by c-Myc deserves further attention but is uncertain at this juncture.
As noted above, p19 ARF is probably a transcriptional target of c-Myc (Dang, 1999) , because the p19 ARF message is initiated at a speci®c promoter in the Ink4 gene that includes Myc E box motifs (C Sherr, personal communication). p19
ARF is dispensable for cell proliferation so it will likely have a speci®c role either in priming death or in mediating death or death sensitization signals. Since it is the only target gene at current which appears to be strictly devoted to apoptosis, analysis of the mechanisms by which cMyc activates its expression may provide a physiological paradigm for death-speci®c transactivation. Other proapoptotic oncogenes are likely to upregulate p19 ARF and it will be important to learn whether c-Myc mediates such eects. Continued investigations of the c-Myc-p19 ARF connection and the regulation and mechanism of action of p19 ARF should provide interesting and important new insights into one pathway through which c-Myc kills cells.
The metabolic enzyme lactate dehydrogenase A (Ldh-A) is a c-Myc target gene recently shown to sensitize cells to a novel glucose-dependent apoptotic pathway (Shim et al., 1997 (Shim et al., , 1998 . Ldh-A is part of the normal anaerobic glycolysis pathway which operates at higher levels in hypoxic cells. In tumor microenvironments, cells further than *0.1 mm from a blood supply are subjected to severe hypoxia which they must adapt to or perish. In addition to recruiting vessels by secreting angiogenic factors, cells adapt to hypoxic conditions by metabolizing glucose without oxygen and overproducing lactic acid aerobically, in a process known as the Warburg eect (Warburg, 1956; Dang, 1999) . Notably, MCF7 breast carcinoma cells deprived of glucose exhibit both c-Myc elevation and signi®cant cell death, which can be blocked by the addition of antisense c-Myc oligonucleotides (Lee et al., 1997) . The identi®cation of Ldh-A as a genetic target of c-Myc may provide a molecular basis for this eect (Shim et al., 1997) . Notably, when Rat1 cells overexpressing Ldh-A are deprived of glucose or are treated with the antimetabolite 2-deoxyglucose, they engage a p53-independent death program, whereas control cell lines merely respond by G0/G1 arrest (Shim et al., 1998) . c-Myc-expressing Rat1 cells also respond to glucose deprivation or 2-deoxyglucose treatment by undergoing apoptosis. The extent of apoptosis in cells expressing either c-Myc or Ldh-A is similar. Ldh-A-expressing cells do not undergo apoptosis following serum deprival, indicating that Ldh-A only sensitize cells to the antiglycotic trigger, but the extent of apoptosis caused by glucose deprival is similar to that caused in c-Myc-expressing cells by serum deprival (Shim et al., 1998) . Bcl-2 suppresses glucose deprival-induced apoptosis in both c-Mycexpressing Rat1 cells and MCF7 carcinoma cells (Lee et al., 1997; Shim et al., 1998) . Therapeutic opportunities are suggested by the ability of other frank tumor cells which overexpress c-Myc to undergo signi®cant apoptosis when treated with 2-deoxyglucose (Shim et al., 1998) . The mechanism of action is unclear at this point but is speculated to involve alteration of the redox state of the cell due to relative increases in the ratio of NAD+ : NADH caused by Ldh-A-dependent generation of NAD+ (Shim et al., 1998) .
Regulation by cytokines and adhesion signals
The apoptotic properties of c-Myc are masked by cytokines and adhesion signals. The role of cytokines was obvious since it was removal of such factors that revealed those properties. An examination of the inhibitory eects of dierent serum growth factors in Rat1 ®broblasts identi®ed insulin-like growth factor-1 (IGF-1) and platelet-derived growth factor (PDGF) as crucial players (Harrington et al., 1994a) . Insulin-like growth factor-II (IGF-II) also had some antiapoptotic activity but it was much weaker. Interestingly, experiments where protein synthesis inhibitors were added indicated that PDGF required protein synthesis to mediate its eects but that IGF-1 did not. Bcl-2 upregulation by PDGF was ruled out and the presumptive genetic targets of PDGF remain to be identi®ed. In contrast, IGF-1 apparently regulates cell death at some posttranslational level. Cell type dierences may be a caveat because in one study in hepatoma cells IGF-1 seemed to promote apoptosis by c-Myc (Xu et al., 1997) . However, antiapoptotic eects of IGF-1 are clearly of wide signi®cance in cancer settings . IGF-1 has many roles in cell growth and dierentiation but survival signals that are mediated by the IGF-1 receptor are mechanistically distinct (O'Connor et al., 1997) . TGF-a also appears to suppress apoptosis by c-Myc, in this case during development of mammary carcinoma in transgenic mice (Amundadottir et al., 1996) . Tissue speci®c dierences are again hinted at because TGF-a mediates its eects through the EGF receptor, but EGF was not found to promote survival in Rat1 cells (Harrington et al., 1994a) . Lastly, activation of the tyrosine kinase receptor Ark (Axl) by its ligand Gas6 (a member of the vitamin K-dependent family of proteins preferentially expressed in quiescent cells) has been reported to suppress apoptosis by c-Myc (Bellosta et al., 1997) . No mechanistic information is available concerning the signaling pathways used by TGF-a or Gas6/ARK.
The IGF-1 survival signal implicated by Harrington and colleagues has been traced from the IGF-1 receptor through a Ras-dependent pathway to phosphatidylinositol 3'-kinase (PI3'K) and the AKT/PKB kinase (Kauman-Zeh et al., 1997) . The PI3'K-AKT pathway has been widely implicated in cell survival mediated by cytokine and cell adhesion receptors, with Ras having an important part in mediating the signal from cytokine receptors (Frisch and Ruoslahti, 1997; Downward, 1998) . At least two AKT substrates are part of the basic apoptosis machinery, Bad and caspase-9, whose proapoptotic activity is each inhibited by AKT phosphorylation (Datta et al., 1997; del Peso et al., 1997; Cardone et al., 1998) . Caspase-9 was implicated recently in the mechanism through which cMyc potentiates cell death (Fearnhead et al., 1998) , so the antiapoptotic eects of IGF-1 might lead here. However, the extent of any role for caspase-9 inhibition in mediating the antiapoptotic eects of IGF-1 remains to be established and it seems reasonable to expect that other substrates will also be important. As noted above, cyclin D3 can potentiate death by c-Myc (Janicke et al., 1996) and recently this cyclin has been reported to be a substrate for AKT (Muise-Helmericks et al., 1998) . It is also conceivable that other Ras eectors may also be involved in mediating IGF-1-generated survival signals, such as those involving Rho or NF-kB (Lebowitz et al., 1995; Mayo et al., 1997) . Lastly, a recent study has implicated CD95/Fas in death by c-Myc (see below) and AKT has been reported to inhibit CD95/Fasdependent death in this context (Rohn et al., 1998) . In summary, the manner in which IGF-1 inhibits apoptosis by c-Myc may prove complex and involve several antiapoptotic pathways.
Cell adhesion also in¯uences the susceptibility of cells to apoptosis by c-Myc. In a study of CHO cells overexpressing c-Myc, cell density was found to alter the susceptibility to death triggered by serum deprivation (Gibson et al., 1995) . Cells cultured at higher densities were less susceptible, arguing that cell-cell interactions may limit death. This observation is reminiscent of density-dependent eects on anoikis in MDCK cells (Frisch and Francis, 1994) . Cellsubstratum interactions also in¯uence susceptibility to c-Myc. For example, primary rat embryo ®broblasts (REFs) transformed by c-Myc and oncogenic Ras will rapidly undergo apoptosis if deprived of matrix adhesion, whereas normal REFs exit to G0 phase for an extended period (McGill et al., 1997) . RGDcontaining integrin ligands also induced apoptosis of such cells, implying that integrin signals are responsible for death suppression. Death was inhibited if cells are plated at high density under conditions which promote cell-cell aggregation, which was implicated to be via cadherins since calcium chelators relieved inhibition. Loss of wild-type p53 lengthened the kinetics but did not abrogate death, consistent with the notion that p53 sensitizes cells to apoptosis c-Myc but is not required. Lastly, REFs cotransformed with activated Src instead of Ras did not undergo apoptosis when deprived of adhesion, probably due to the role of Src in integrin signaling (Inoue et al., 1995; Frisch and Ruoslahti, 1997; Parsons and Parsons, 1997) .
Another study using primary chick embryo fibroblasts (CEFs) also implicated matrix signals in the susceptibility to apoptosis by c-Myc (Crouch et al., 1996) . In this study, ®bronectin and collagen matrix reduced apoptosis caused by serum withdrawal, and substratum coated with an anti-b1 integrin antibody produced a similar eect. Consistent with a role for integrin signaling in governing susceptibility to c-Myc, proteolysis of the integrin-associated eector kinase FAK was observed to be an early event in cells committed to undergo apoptosis (Crouch et al., 1996) . Adhesion signals involving Src and APC/b-catenin regulate both apoptosis and c-Myc expression (Barone and Courtneidge, 1995; He et al., 1998) , consistent with the possibility of some role for an adhesion-dependent signal in modulating the ability of c-Myc to activate cell death. Further investigation is needed to assess whether loss of integrin-mediated adhesion is a triggering event or a correlate of apoptosis by c-Myc. In addition, given the ®ndings of these studies, it would be interesting to determine whether ectopic expression of activated Src or an uncleavable FAK construct could block apoptosis by c-Myc which is elicited by serum or matrix deprival. One might predict an overlap in the processes used by IGF-1 and integrins to suppress the lethality of c-Myc, insofar as there is crosstalk between the IGF-1 receptor and integrin circuitry [e.g. a v b 3 (Zheng and Clemmons, 1998) and b1 receptors (Guilherme and Czech, 1998) . Moreover, integrins also access the PI3'AKT signal transduction pathway to promote cell survival (Frisch and Ruoslahti, 1997; Clark et al., 1998; Kumar, 1998) .
Regulatory connections between c-Myc and death receptors
Several studies reveal regulatory circuits that link cMyc to death receptors (see Figure 3) . Members of the tumor necrosis factor (TNF) or APO transmembrane receptor family are expressed on the surface of many mesenchymal and epithelial cells. They have complex roles that extend beyond death signaling including possible roles in proliferation (e.g. Zornig et al., 1998) . TNF family receptors use an adaptor system to directly activate caspases and they are subject to complex modulation (Ashkenazi and Dixit, 1998) . Ligand binding causes receptor homotrimerization and recruitment on the cytoplasmic face of the membrane of a death-inducing signaling complex (DISC), which includes the adaptors FADD and TRADD and procaspase-8 as crucial physiological death eectors (Juo et al., 1998; Varfolomeev et al., 1998; Yeh et al., 1998; Zhang et al., 1998) . A brief outline of the CD95/ Fas and TNf receptor systems follows since c-Myc has been implied to act both upstream and downstream of each (Janicke et al., 1994; Klefstrom et al., 1994 Klefstrom et al., , 1997 Hueber et al., 1997; Wang et al., 1998a) .
CD95/Fas activates death by two routes that are either independent or dependent of mitochondria, as favored in Type I or Type II cells, respectively (Scadi et al., 1998) . In type I cells, recruitment of FADD leads to ecient binding and activation of caspase-8 activity, which proceeds to activate caspase-3 and cause cell demise. In type II cells, caspase-3 is activated by a more roundabout route that involves mitochondria. In this case, activation of caspase-8 occurs with delayed kinetics and is weaker. With time the proapoptotic Bcl-2 family protein Bid is cleaved and activated by the active caspase-8 which is produced, and active Bid proceeds to induce cytochrome c release and caspase-9-dependent activation of caspase-3 Luo et al., 1998) . Antiapoptotic Bcl-2 proteins inhibit CD95/Fas-dependent apoptosis in Type II cells, because of the involvement of mitochondria, but not in Type I cells, since mitochondria are not signi®cantly involved. CD95/Fas also activates the Jnk pathway but there is con¯icting evidence regarding how. In one study where caspase-8 was genetically ablated, Jnk activation by CD95/Fas was defective (Juo et al., 1998) . However, other studies imply activation occurs upstream or in parallel to FADD (Wajant et al., 1998) , possibly through the putative CD95/Fasinteracting adaptor protein Daxx, which is proposed to activate the Jnk pathway through binding the Mekk1 kinase Ask1 (Yang et al., 1997; Chang et al., 1998) . These interactions await physiological confirmation as do those with other factors reported to modulate CD95/Fas in model systems, including the proapoptotic adaptor protein Faf and the antiapoptotic ubiquitin-like protein sentrin (Chu et al., 1995; Okura et al., 1997) . The TNF-R also uses FADD and caspase-8 to activate cell death, but its DISC includes the other adaptor proteins TRADD, RIP, and the TRAFs (Ashkenazi and . TRADD is a proapoptotic intermediary adaptor between the receptor and FADD. RIP also binds TRADD and is thought to participate in activation of the Jnk pathway, which also involves TRAFs and possibly Ask1 (Ashkenazi and Nishitoh et al., 1998) . TRAFs, in particular TRAF2, are implicated in activation of an antiapoptotic pathway that stimulates NFkB activation via IkB inactivation (Ashkenazi and .
The initial connection between c-Myc and death receptors was suggested by ®ndings that c-Myc is a crucial determinant of the cytotoxic response to TNF-a (Janicke et al., 1994; Klefstrom et al., 1994) . Subsequent work on the mechanism has argued that c-Myc acts by in¯uencing the delicate balance between the survival and death signaling pathways which are simultaneously activated by this factor (Klefstrom et al., 1997) . Using a conditional Rat1 expression system, these authors showed that induction of c-Myc impaired the ability of TNF-a to activate NF-kB and Jnk. The inhibition of NF-kB was implied to be important because ectopic expression of NF-kB made cells refractory to the ability of c-Myc to sensitize them to TNF-a. While this study did not examine a role for Jnk, nor did it establish if NF-kB inactivation was necessary for the eect of c-Myc (only that it was sucient to block it), these results infer that c-Myc may sensitize cells to TNF-a by impeding the TRAF2-dependent survival pathway which is thought to be responsible for coactivation of NF-kB and Jnk (Natoli et al., 1997; Reinhard et al., 1997) . It will be important to explicitly establish TRAF2 involvement, however, because the ability of TNF-a to still activate NF-kB in TRAF2-de®cient cells implies there are other ways to do it . Notably, c-Myc did not block TNF-a-dependent elevation of p53 which occurred, indicating that c-Myc only aected a particular signaling pathway(s) not involved in activation of TNF-a target genes (Klefstrom et al., 1997) . Interestingly, as noted above, a transactivation-independent function of p53 was implied to be necessary for c-Myc sensitization, because inhibiting p53 oligomerization by a dominant inhibitory approach did not mimic the resistance seen in p53 null cells. Taken together, the results hinted that c-Myc acts at a step proximal to TRAF2 which regulate TNF-a ± dependent activation of NF-kB and Jnk. Further investigation is required to determine the exact mechanism and the apparent regulatory linkage with the TNF receptor.
c-Myc may act both upstream and downstream of the TNF-R family member CD95/Fas (Hueber et al., 1997) . Similar to the case with TNF-a, Rat1 ®broblasts were not susceptible to killing by CD95/Fas ligand unless c-Myc was expressed. This indicated that c-Myc was necessary or perhaps that it sensitized cells to this factor (Evan and Littlewood, 1998) . The latter possibility is supported by evidence that transcription of the CD95/Fas ligand is targeted for activation by many apoptotic stimuli, including TCR activation through NF-kB (Kasibhatla et al., 1999) , DNA damage and other stresses through NF-kB, the Jnk pathway (AP-1), and Egr-3 (Faris et al., 1998; Kasibhatla et al., 1998; Mittelstadt and Ashwell, 1998) . Sensitization by c-Myc in Rat1 ®broblasts was not due to upregulation of CD95/Fas or CD95/Fas ligand, although recent evidence suggests that CD95/ Fas ligand may be a target for activation by c-Myc in other cell types (Wang et al., 1998a) . In any case, the biological data indicates that c-Myc can sensitize cells to CD95/Fas ligand by acting at some point downstream of the receptor.
Evidence was also presented in support of the hypothesis that CD95/Fas is necessary for apoptosis by c-Myc elicited by serum deprival (Hueber et al., 1997) . First, neutralizing antibodies to the CD95/Fas ligand inhibited death in a dose-dependent manner when added to serum deprived cells. Consistent with a speci®c role in apoptosis, the antibodies did not aect the ability of c-Myc to drive cell division in the absence of serum. Second, embryo ®broblasts from lpr or gld mice which have defective CD95/Fas and CD95/Fas ligand genes, respectively, were refractory to apoptosis by c-Myc. Finally, ectopic expression of a FADD dominant inhibitory mutant also inhibited the cytotoxic eects of c-Myc. These results all pointed to an eector role for CD95/Fas in c-Myc killing in Rat1 ®broblasts. A subsequent study aimed at identifying where c-Myc acted traced the point downstream of ligand binding but actually upstream of FADD binding (Rohn et al., 1998) . A FADD-independent mechanism is also implied by the ability of overexpressed c-Myc to kill FADD nullizygous mouse embryo ®broblasts (Yeh et al., 1998) . FADD is the only physiologically validated eector of CD95/Fas so if it is dispensable some other proapoptotic CD95/Fasbinding adaptor protein may be involved, perhaps Daxx or Faf. A strong prediction of the hypothesis that CD95/Fas is crucial for apoptosis by c-Myc is that tumor development in myc transgenic animals should proceed more rapidly in lpr and gld backgrounds and in caspase-8 +/7 mice as compared with caspase-3 +/7 or caspase-9 +/7 mice (which would be predicted to be susceptible based on the ®nding that caspase-9 is responsible for mediating the proapoptotic action of cMyc in cell free-extracts [Fearnhead et al., 1998] ). Further investigations are required to validate the role of CD95/Fas and to uncover the basis for its apparent regulatory interactions with c-Myc. Along with progress in understanding the connections to TNF receptor, studies of the CD95/Fas-c-Myc linkage seem (Hueber et al., 1997; Rohn et al., 1998) . c-Myc may sensitize cells to TNF-a by inhibiting RIP/TRAF2-dependent antiapoptotic pathways that lead to activation of NF-kB and Jnk (Klefstrom et al., 1997) . How widely these connections are used in dierent cells is not yet clear likely to give deeper insights into how c-Myc activates or sensitizes cells to apoptosis.
Role of interaction with the cell fate adaptor protein Bin1
Recent work from our laboratory suggests that interaction with the NTD-interacting adaptor protein Bin1 is required for c-Myc to activate apoptosis but not to drive cell proliferation (D Sakamuro, J DuHadaway, D Ewert and GC Prendergast, manuscript submitted). Bin1 was initially identi®ed in a screen for MB1-binding proteins but its interaction with c-Myc requires both of the conserved Myc boxes (Sakamuro et al., 1996) . Bin1 inhibits the oncogenic and transcriptional transactivation properties of c-Myc in a binding domain-dependent manner (Elliott et al., 1999; Sakamuro et al., 1996) . Bin1 will also inhibit the oncogenic properties of adenovirus E1A, papilloma virus E7, and mutant p53, through domains that are dispensable for eects on c-Myc (Elliott et al., 1999) . Investigations of the status of the Bin1 gene (WechslerReya et al., 1997b) in tumor cells supports the hypothesis that Bin1 is a tumor suppressor with important growth regulatory roles (Sakamuro et al., 1996; Wechsler-Reya et al., 1997b; Elliott et al., 1999; Mao et al., 1999 ; J DuHadaway, K Ge and GC Prendergast, manuscripts submitted).
In primary chick ®broblasts, which are susceptible to both apoptosis and malignant transformation by deregulated c-Myc alone, inhibition of Bin1 by antisense and dominant inhibitory methods suppressed serum deprival-induced apoptosis but not proliferation or malignant transformation induced by c-Myc. In particular, overexpression of the c-Myc binding domain of Bin1 inhibited apoptosis, implying that cMyc-Bin1 interactions are required to mediate cell death. Similar results were obtained in BRK epithelial cells under conditions where p53-independent cell death by c-Myc was induced, arguing that Bin1 acts through a p53-independent mechanism. In Rat1 ®broblasts, Bin1 suppression inhibited apoptosis to a similar degree as Bcl-2 and allowed outgrowth of cells cultured in suboptimal serum conditions (Sakamuro et al., manuscript submitted) . Under conditions where Bin1 inhibition blocked apoptosis by c-Myc, no eects were seen on the message levels of three Myc target genes implicated in apoptosis (ODC, Cdc25A, and p19 ARF ). Bin1 includes structural features found in signaling proteins (i.e. SH3 domain) so it may act to trigger apoptosis in a transcription-independent manner. Alternately, since Bin1 can inhibit the transactivation properties of c-Myc in transient assays (Elliott et al., 1999b) , there may be appropriate regulation of an unidenti®ed target gene(s) relevant to apoptosis. Overexpression of Bin1 blocks transformation by cMyc+Ras apparently by promoting the ability of cMyc to drive death (unpublished observations). Bin1 overexpression kills tumor cells lacking endogenous Bin1 but it does not kill normal cells (Sakamuro et al., 1996; Wechsler-Reya et al., 1998; Elliott et al., 1999a) , arguing that it is not an executioner but an adaptor protein that links c-Myc to the executioner machinery. Consistent with some regulatory role in apoptosis, Bin1 moves between the nucleus and cytosol and it is a genetic target for transcriptional regulation by NF-kB (Mao et al., 1999) . The relative ease with which one can obtain c-Myc-overexpressing cell clones that are resistant to apoptosis in vitro (Dhanaraj et al., 1996) is consistent with observations that Bin1 is often inactivated in tumor cells by epigenetic mechanisms, which are relatively malleable (K Ge, J DuHadaway, D Sakamuro and GCP Prendergast, manuscripts submitted). Interestingly, Bin1 induces apoptosis in tumor cells which lack endogenous Bin1 through a largely caspase-independent mechanism that is not associated with chromatin collapse or nucleosomal DNA degradation (K Elliot, K Ge and GC Prendergast, manuscript submitted), features reminiscent of the death produced by c-Myc in the presence of caspase inhibitors (McCarthy et al., 1997) .
Existing information about Bin1 suggests that it is a cell fate adaptor protein that coordinates the complex decisions made when cells exit the cell cycle (e.g. enter G0, commit to die, dierentiate, etc.). For example, in cells where c-Myc is normal and can be downregulated when there is a signal to exit the cell cycle, Bin1 helps to inhibit proliferation and to promote dierentiation (Wechsler-Reya et al., 1998; Mao et al., 1999) . In contrast, if c-Myc expression is enforced and as a result cells cannot exit the cell division cycle, Bin1 is necessary for c-Myc to engage the ensuing apoptotic program (Sakamuro et al., manuscript submitted) . Several ®ndings argue for complex adaptor roles in cells for Bin1 . First, the nuclear tyrosine kinase c-Abl was shown recently to interact with but not phosphorylate Bin1 in vivo (Kadlec and Pendergast, 1997) . c-Abl binding is mediated by the SH3 domain of Bin1 (Kadlec and Pendergast, 1997) , which is dispensable for its association with c-Myc (Sakamuro et al., 1996; Elliott et al., 1999) . A fraction of c-Abl in cells is reported to be activated at focal adhesions where integrins are located (Lewis et al., 1996; Taagepera et al., 1998) , so since apoptosis by c-Myc is in¯uenced by integrin signals (Crouch et al., 1996) there may be links via this route to c-Abl activation. How Bin1 and c-Abl in¯uence the action of each other in proliferation, dierentiation, and apoptosis remains to be determined, however. Second, Bin1 is subjected to extensive alternate splicing, especially in neurons (Butler et al., 1997; Ramjaun et al., 1997; Tsutsui et al., 1997; Wechsler-Reya et al., 1997b; Ramjaun and McPherson, 1998) , and it is localized to the cytosol as well as the nucleus in certain cells (Butler et al., 1997; Kadlec and Pendergast, 1997; Wechsler-Reya et al., 1998) . The N and C-terminal regions of Bin1 are related to amphiphysin, a neuronal protein that is a paraneoplastic autoimmune antigen in breast and lung cancer (David et al., 1994; Dropcho, 1996) . The same regions are also related to Rvs167 and Rvs161, two negative regulators of the cell cycle in yeast (Crouzet et al., 1991; Bauer et al., 1993) [Bin1 is related but not homologous since it cannot complement Rvs functions (Sakamuro et al., 1996) ]. Amphiphysin and brainspeci®c splice forms of Bin1, also termed amphiphysin II or amphiphysin isoform, have been implicated in receptor-mediated endocytosis (David et al., 1996; Wigge et al., 1997; Owen et al., 1998) . RVS167 and RVS161 have been implicated in endocytosis and karyogamy (Munn et al., 1995; Brizzio et al., 1998) .
However, non-neuronal splice forms of Bin1 appear unlikely at this point to be involved in endocytosis, because only neuronal splice forms include the exons which encode clathrin-binding determinants needed for localization to endocytotic vesicles (Ramjaun and McPherson, 1998) . The endocytosis connection in neurons might re¯ect a link in those cells between cell survival and the achievement of a dierential and synaptically active state, which would be associated with neurotransmitter release and hence membrane tracking. If Bin1 has endocytotic roles outside neurons, given the links of c-Myc to CD95/Fas and TNF-R, it is tempting to speculate about connections to mechanisms used by p53 to control apoptosis by cell surface tracking of CD95/Fas (Bennett et al., 1998) , or to potential requirements of CD95/Fas internalization via endocytosis for the generation of a competent death signal (A Ashkenazi, personal communication). Third, the orthologs of Bin1 in yeast can in¯uence cytoskeletal regulation and interact with a functionally unde®ned transmembrane protein (Sivadon et al., 1995 (Sivadon et al., , 1997 Breton and Aigle, 1998) . These roles hint of links to cell surface receptors and perhaps also to actin cytoskeletal rearrangements that are involved in membrane blebbing (zeosis), a process which has been reported to involve integrins, actin depolymerization, and Jnk activation events (Laster and Mackenzie, 1996; Huot et al., 1998) . Further investigations are required to establish whether any of these connections are relevant to how the Bin1 gene acts in apoptosis and how its proapoptotic functions are controlled differentially from its functions in endocytosis, proliferation, and dierentiation.
Modi®ed dual signal model for c-Myc function
Two general models for how apoptosis is induced by c-Myc have been enunciated, the so-called con¯ict and dual signal models (Harrington et al., 1994b; Packham and Cleveland, 1995) . Figure 4 outlines each model. In the con¯ict model, apoptosis is proposed to be an indirect or distal response of the cell to an inappropriate growth signal generated by deregulated c-Myc. This model is a default and does not postulate a new function for c-Myc beyond that in cell division. In the dual signal model, Myc is proposed to induce apoptosis by directly regulating a death eector system(s). This system presumably includes downstream target genes that are death-speci®c but formally includes interactions with death eector signaling protein(s). The dual signal model postulates that c-Myc functions as regulator of cell death as well as cell division. Its strongest prediction is that at some levels the mitogenic and apoptotic properties of c-Myc should be distinct and hence separable. However, rudimentary structure-function analysis illustrates complete genetic overlap on c-Myc , and as noted above, no functional divergence has occurred even in retroviral myc oncogenes, where selective pressures in evolution would be expected to produce rapid divergence if this were possible. Moreover, Max association and DNA binding is required for both apoptosis and proliferation (Amati et al., 1993b) . Thus, an inescapable conclusion from structural and biological evidence is that c-Myc coordinately primes cell death as it drives cell proliferation.
Although the functions of c-Myc can not be separated at the level of the protein, there is evidence that these functions can be separated on the basis of separate eector pathways. We propose that growth and death priming or sensitization functions are integrated in one pathway and that death triggering is mediated through a separate pathway (Figure 4 , part 3 and Figure 5 ). The following lines of evidence support this modi®ed dual signal model. First, it is possible in certain cases to arrest cells containing deregulated c-Myc without killing them (Gibson et al., 1995; Packham and Cleveland, 1996; Ryan and Birnie, 1997) . For example, c-Myc-expressing 32D cells undergo growth arrest in the absence of cell death when treated with non-hydrolyzable analogs of cAMP (Packham and Cleveland, 1996) . IL3 withdrawal will still trigger cell death, indicating that IL3 and cAMP in¯uence dierent signals that in¯uence cell fate, consistent with a multiple eectors model (Packham and Cleveland, 1996) . These observations are consistent with the demonstration that cAMP analogs will inhibit the ability of c-Myc to generate activators of apoptosis as measured in cell-free extracts . A second line of support for dual signal is Figure 4 Con¯ict and dual signal models for Myc function. The models are adapted from Harrington and Evan (Harrington et al., 1994b) . In con¯ict, c-Myc functions solely in cell proliferation; apoptosis is the cellular response to an inappropriate signal from c-Myc when growth arrest signals are extant. In dual signal, cMyc coordinately induces apoptosis and cell proliferation through dierent pathways; survival factors suppress the apoptosis pathway. In the modi®ed dual signal model discussed in the text, c-Myc coordinately induces proliferation and primes apoptosis through one pathway and triggers apoptosis through a second pathway. In this model, survival factors suppress the apoptosis trigger pathway provided by the identi®cation of target genes which appear to be speci®cally involved in apoptosis. Activation of p19 ARF by c-Myc, which is thought to be transcriptional (Dang, 1999) , has been so implicated . Third, inhibition of CD95/Fas signaling blocks apoptosis but not proliferation by cMyc in Rat1 ®broblasts (Hueber et al., 1997) . CD95/ Fas ligand (CD95L/FasL) may be an additional target of c-Myc in certain cell types (Wang et al., 1998a; D Sakamuro and GC Prendergast, unpublished observations) . Lastly, interaction between c-Myc and Bin1 is necessary to activate apoptosis but dispensable to drive proliferation or malignant transformation, in both ®broblast and epithelial cell models (Sakamuro et al., manuscript submitted) . These results arguably oer the most direct support for the dual signal model insofar as they make a distinction in functions at the level of a binding protein.
Other reasons support the notion that the proapoptotic eector functions of c-Myc can be further discussed into`death priming' and`death triggering' steps. One reason is that protein synthesis inhibitors do not block c-Myc-mediated cell death Wagner et al., 1994) . This is telling because it is also clear that Max binding (Amati et al., 1993b) and therefore transcriptional regulation of target genes by c-Myc is required for it to induce death (e.g. p19 ARF ) (Dang, 1999) . A second reason is inferred by the structure of Bin1, which while necessary for apoptosis by c-Myc does not have features of a transcription factor but rather features of a signal transduction protein (e.g. an SH3 domain). Bin1 may be linked to transcriptional programs, though, since it can inhibit the transactivation properties of c-Myc (Elliott et al., 1999) .
We hypothesize that c-Myc`primes' death through transcriptional regulation of target genes, and triggers' death though some signaling mechanism that involves productive interactions between Bin1 and the`primed' target gene products (see Figure 5) . Priming would allow the Max requirement to be accommodated and triggering would provide a role for Bin1 consistent with its requirement and its structure as a signaling adaptor. If priming and triggering are separable, then c-Myc should still prime death in tumor cells where Bin1 is missing or inhibited. There is some support for this idea based on the ability of c-Myc to induce latent activators of caspase activity in cell-free extracts from tumor cells where Bin1 is lost (Fearnhead et al., 1997 (Fearnhead et al., , 1998 Ding et al., 1998) and the ability of Bin1 to trigger death in such cells upon its reintroduction (K Elliott et al., manuscript submitted). The triggering mechanism may have two parts, one that activates caspases and a second that serves to commit cells to a death decision. That these signals are separable is suggested by the ability of caspase inhibitors to block many classical features of apoptosis by c-Myc, but not the commitment to undergo cell death (McCarthy et al., 1997) . Examples of caspase-independent apoptosis associated with some role for the subnuclear domain termed ND10 (Ascoli and Maul, 1991) have appeared recently in studies of the leukemia breakpoint gene PML (Quignon et al., 1998; Wang et al., 1998b) . Investigations of caspase-independent signals, possibly involving Bin1, may provide new insights into how cells commit to undergo apoptosis and how cell death is triggered.
Summary and future directions
Recent advances strongly support a dual function model for c-Myc as a co-ordinate activator of cell proliferation and apoptosis. Both functions are intrinsic to c-Myc but evidence for speci®c death eector pathways is emerging. Such eector signals are hypothesized to include`priming' and`triggering' mechanisms associated with separable caspase-dependent and caspase-independent processes. Myc target genes implicated at some level include ODC, lactate dehydrogenase-A, p19 ARF , and possibly certain cell cycle regulators. The cytokines IGF-1 and PDGF regulate the apoptotic properties of c-Myc as do cell adhesion signals. The ®ndings that c-Myc sensitizes the cells to death receptor signals from the TNF receptor and CD95/Fas, and may require signals from the latter receptor to kill cells, hint at regulatory links whose continued investigation may provide deeper insights into apoptosis by c-Myc and other oncogenes. Lastly, a speci®c role for the c-Myc-interacting cell fate adaptor Bin1 in apoptosis suggests the existence of a heretofore unrecognized nuclear-based death eector signaling pathway used by c-Myc. The model proposes that c-Myc activates proliferation and primes apoptosis through one pathway and triggers apoptosis through a second and mechanistically distinct pathway. The inability of protein synthesis inhibitors to block apoptosis in cells expressing deregulated c-Myc suggests that the apoptotic program is primed by gene regulation and triggered by a separate signaling process. In the model, death priming and proliferation involves regulation of speci®c target genes by c-Myc/Max complexes. The links between TRRAP and the transcription complex SAGA suggest it may be involved with the proliferation pathway. p107 interaction is proposed to co-ordinate gene regulation with the cell cycle. Max and gene regulation is required for proliferation and death priming but may be dispensable for death triggering. Conversely, Bin1 is dispensable for proliferation and death priming but necessary to trigger death once it is primed. p53 may contribute to sensitizing cells to the trigger, but is mechanistically distinct from Bin1 since the latter can mediate p53-independent death. Survival signals from cytokine and adhesion receptor pathways are proposed to target the triggering pathway for inactivation, possibly by targeting Bin1 itself since it is a phosphoprotein (Wechsler-Reya et al., 1997a) While the new advances provide a stronger foundation for understanding the intrinsically dual nature of c-Myc function in growth and apoptosis, many pressing questions remain about how it kills cells. In particular, one would like to identify the molecular basis for the stochastic aspect of death. While sensitization of cells to apoptosis may`lower the bar' to trigger death by minor insults (Evan and Littlewood, 1998) , the mechanism by which cells reach the threshold to commit to engage the death program is still quite obscure. Caspase activation looks to be coordinated with but perhaps separable from the death commitment signal. To assess the signi®cance of dierent caspases as well as components of the executioner machinery, death receptor DISCs, etc., it will be necessary to examine the eects of various null backgrounds on apoptosis by c-Myc or the eects on tumor development and apoptosis in crosses between various`knockout' animals and myc transgenic mice. Pinpointing the death commitment signal may provide a powerful tool to address advanced cancer, since it would allow one to manipulate the threshold which must be crossed to commit to death. One question is whether there are cell cycle regulators or target genes with an unambiguous role in apoptosis. Another is whether the proapoptotic E2F member E2F1 has any role in mediating death by c-Myc, because of some evidence that c-Myc acts upstream of Rb and E2F in cell cycle regulation (Amati et al., 1998) . What is the exact relationship between c-Myc and p53 or between c-Myc and the TNF receptor or CD95/Fas? What are the targets of the antiapoptotic signals mediated by cytokines and matrix? These questions also impinge greatly on therapeutic possibilities in cancer. While cMyc investigations have traditionally presented a mine®eld to the researcher, the pay-o for advances in understanding is likely to continue to be signi®cant to our grasp of basic cell biological processes such as cell fate determination as well as to applied problems in cancer.
